HSBC Holdings
ADCT icon

HSBC Holdings’s ADC Therapeutics ADCT Stock Holding History

HSBC Holdings’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40K Buy
10,577
+56
+0.5% +$221 ﹤0.01% 2822
2025
Q4 		$37.7K Hold
10,521
– – ﹤0.01% 2880
2025
Q3 		$41.6K Buy
+10,521
New +$33.2K ﹤0.01% 2653

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HSBC Holdings's ADCT Position: Q1 2026 in Review

HSBC Holdings increased its ADC Therapeutics (ADCT) stake by 0.53% in Q1 2026, buying an estimated $221 and bringing the position to 10,577 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #2822.

HSBC Holdings first reported a position in ADCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $41.6K in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • HSBC Holdings held 10,577 shares of ADC Therapeutics worth $40K as of Q1 2026.
  • HSBC Holdings bought 56 ADC Therapeutics shares in Q1 2026, an estimated $221.
  • ADC Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2822 holding.
  • HSBC Holdings first reported a position in ADC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • HSBC Holdings's ADC Therapeutics position peaked at $41.6K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.